Dubai Government Grants Insurance Reimbursement for Biomerica’s EZ Detect™ Colorectal Disease Screening Test
26 Settembre 2023 - 2:19PM
Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that
the Dubai government has officially approved insurance
reimbursement for the EZ Detect colorectal disease at-home
screening test, which is designed to detect an early warning sign
of colorectal cancer and other colorectal diseases. Colorectal
cancer (“CRC”) is the second most common cause of cancer death in
the UAE [1].
Key benefits of the EZ Detect colon diseases
test include:
- Early
Detection: EZ Detect is designed to identify occult
(hidden) blood in the stool, which can be an early indicator of
colorectal diseases, including cancer.
-
User-Friendly: The test is easy to use and
requires no special preparation, dietary restrictions, or
medications. Unlike other tests, it does not require a person to
touch or handle stool and can be completed in the privacy of one’s
home without the unpleasantries of handling and mailing stool
samples or providing them to a laboratory.
-
Affordable: Insurance reimbursement ensures that
the cost of the test is covered for eligible individuals.
- Peace
of Mind: Regular screening with EZ Detect can provide
peace of mind and help detect potential issues before they become
more serious.
Colorectal cancer is a prevalent and potentially
life-threatening condition that affects millions of individuals
worldwide. According to the World Health Organization (WHO), in
2020 alone, more than 1.9 million new cases of colorectal cancer
and more than 930,000 deaths due to colorectal cancer were
estimated to have occurred worldwide. The organization estimates
that colorectal cancer is the third most common cancer worldwide
and is the second leading cause of cancer-related death
worldwide.
To change this unfortunate dynamic, early
detection is key to effective treatment and improved patient
outcomes. The EZ Detect test offers a simple and convenient
solution for individuals to assess their colorectal health in the
comfort of their own homes. The EZ Detect™ colon disease screening
test is the simplest at-home test to detect hidden (occult) blood
in a person’s stool, which Is an early warning sign of colorectal
cancer. With the product’s ease of use, a person simply places an
EZ Detect™ test pad on top of toilet water after a bowel movement.
A change in the test pad’s color to blue/green, which would appear
within two minutes, indicates the presence of blood in the stool.
The pad is then simply flushed down the toilet. Patients who see a
positive result should consult with their physician for next
steps.
In a study performed by Johns Hopkins
University, EZ Detect™ was preferred 10 to 1 by patients over
another fecal occult blood test. Published studies have also
indicated that the best colorectal screening test is “the one that
gets it done.” [2] Other colorectal screening tests require
handling of the stool and sending the stool sample to a lab for
processing, which can prove cumbersome. Because of the unpleasant
difficulties of handling and mailing stool samples, a high
percentage of these competing tests are never completed by
patients[3]. This potentially increases the risk for delayed
detection of colorectal cancer.
The EZ Detect™ test does not require handling of
the stool, is simple to perform and provides results at home within
just two minutes in order to assist with early screening. According
to the American Cancer Society, colorectal cancer detected early on
while still localized (not spread) suggests a five-year survival
rate of 91%.
“We are excited that the Dubai government has
recognized the importance of early colorectal disease detection and
has chosen to support the reimbursement of our EZ Detect test,”
said Zack Irani, CEO of Biomerica. “This decision will undoubtedly
save lives by enabling more people to access affordable and
convenient screening for colorectal diseases. We remain dedicated
to our mission of advancing and democratizing easier access to
healthcare solutions that make a difference in people’s lives.”
Biomerica is proud to contribute to Dubai’s
efforts to improve public health by making this crucial screening
tool more accessible to its citizens. The government’s insurance
reimbursement for the EZ Detect colon diseases test is a testament
to Dubai’s commitment to public health and the wellbeing of its
residents. Biomerica looks forward to continuing its partnership
with healthcare providers and insurers to ensure that this
essential screening tool reaches as many individuals as
possible.
For further information about the EZ Detect
Product, please visit www.ezdetect.com
About Biomerica (NASDAQ:
BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical
technology company that develops, patents, manufactures and markets
advanced diagnostic and therapeutic products used at the point of
care (in home and in physicians’ offices) and in hospital/clinical
laboratories for detection and/or treatment of medical conditions
and diseases. The Company’s products are designed to enhance the
health and well-being of people, while reducing total healthcare
costs. Biomerica’s primary focus is on gastrointestinal and
inflammatory diseases where the Company has multiple diagnostic and
therapeutic products in development.
- Humaid O. Al-Shamsi, Amin M. Abyad, and Saeed Rafii , A
Proposal for a National Cancer Control Plan for the UAE:2022–2026.
Clin. Pract. 2022, 12, 118–132.
- Lansdorp-Vogelaar, I., A.B. Knudsen, and H. Brenner,
Cost-effectiveness of colorectal cancer screening - an overview.
Best Pract Res Clin Gastroenterol,
2010. 24(4): p. 439-49.
- Navarro, M., et al., Colorectal cancer population screening
programs worldwide in 2016: An update. World J Gastroenterol, 2017.
23(20): p. 3632-3642.
Safe Harbor Statement
The Private Securities Litigation Reform Act of 1995 provides a
"safe harbor" for forward-looking statements. Certain information
included in this press release (as well as information included in
oral statements or other written statements made or to be made by
Biomerica) contains statements that are forward-looking, such as
statements relating to the efficacy of the Company’s EZ Detect and
other tests, FDA clearance of the Company’s products, possible
in-store offering of EZ Detect, the number of stores where the EZ
Detect and other products are or will be sold or available, the
rapidity of testing results, negotiations with existing and new
domestic and international distribution partners, uniqueness of the
Company’s products, test result accuracy of products, potential for
the products to detect signs of cancer and other diseases, pricing
of the Company’s test kits, demand for domestic or international
orders, potential revenues from the sale of the EZ Detect test in
the CVS pharmacy system or through other distribution channels, or
from the sales of other products, availability of the Company’s
test kits, and patent protection on any of the Company’s products
or technologies. Such forward-looking information involves
important risks and uncertainties that could significantly affect
anticipated results in the future, including, without limitation:
results of studies testing the efficacy of the Company’s EZ Detect
test, InFoods tests and other products; regulatory approvals
necessary prior to commercialization of the Company’s products;
availability of the Company’s test kits and other products;
capacity, resource and other constraints on our suppliers;
dependence on our third party manufacturers; dependence on
international shipping carriers; governmental import/export
regulations; demand for our various tests and other products;
competition from other similar products and from competitors that
have significantly more financial and other resources available to
them; governmental virus control regulations that make it difficult
or impossible for the company to maintain current operations; the
Company’s ability to comply with current and future regulations in
the countries where our products are made and sold and the
Company’s ability to obtain patent protection on any aspects of its
rapid test technologies. Accordingly, such results may differ
materially from those expressed in any forward-looking statements
made by or on behalf of Biomerica. Additionally, potential risks
and uncertainties include, among others, fluctuations in the
Company's operating results due to its business model and expansion
plans, downturns in international and or national economies, the
Company's ability to raise additional capital, the competitive
environment in which the Company will be competing, and the
Company's dependence on strategic relationships. The Company is
under no obligation to update any forward-looking statements after
the date of this release.
Corporate Contact:
Zack Irani949-645-2111zirani@biomerica.com
Source: Biomerica, Inc.
Grafico Azioni Biomerica (NASDAQ:BMRA)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Biomerica (NASDAQ:BMRA)
Storico
Da Set 2023 a Set 2024